News

As per the collaboration, which was originally signed in August 2009, the companies will leverage Silence’s proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate

Reportedly, the samples were evaluated in different parameters like: brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to

Revenues totaled $1.4m, as compared to $3m during the same period in 2008, a decrease of 54%. The decrease in revenues was primarily due to a decrease in

Alcon is expected to immediately assume all marketing, promotion and sales of Durezol. The management of Alcon is continuing to evaluate options to acquire Zirgan, an antiviral recently

The companies are expected to develop novel conjugates of Dicerna’s DsiRNA molecules and Ipsen’s peptide targeting vectors in the therapeutic areas of oncology and endocrinology. James Jenson, co-founder

Oxygen Biotherapeutics said that Dermacyte Oxygen Concentrate is the first product in a cosmetic line which is presently under development. It uses the company’s patented Oxycyte technology, an

The parties to the agreement are: California-based AMC, Hong Kong-based Delta Group Investments (DGI) and Washington-based TNS. AMC is a highly experienced direct mail marketing company. DGI is

MoxDuo CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain. In accordance with the recently approved IND

Melior Discovery has developed expertise in screening compounds for potential therapeutic activity in animal models. Melior is expected to apply this expertise to the evaluation of large numbers